{
    "relation": [
        [
            "",
            "Combination Arm (FluCAM)",
            "Fludarabine Alone"
        ],
        [
            "Description",
            "Participants received both fludarabine (Fludara) and alemtuzumab (Campath) intravenously. Initial escalation of alemtuzumab from 3 to 30 mg (escalation can take up to 14 days). Up to six cycles of fludarabine 30 mg/m^2 intravenous (IV) followed by alemtuzumab 30 mg IV on the first 3 days of each 28 day cycle.",
            "Participants received fludarabine monotherapy 25 mg/m^2 IV daily for the first 5 days of each 28 day cycle for up to 6 cycles."
        ]
    ],
    "pageTitle": "Fludarabine (Fludara\u00ae) Plus Alemtuzumab (CAMPATH\u00ae, MabCampath\u00ae) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00086580?sect=Xh015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989234.2/warc/CC-MAIN-20150728002309-00026-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 868852199,
    "recordOffset": 868835875,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Treatment was from initiation of study drug(s) to 4 weeks after last administration of study drug. Follow-up was for those without disease progression and ended upon disease progression or primary endpoint analysis whichever came first. Observation included those with disease progression who were observed for alternative rx and overall survival. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: FluCAM [Fludara + Campath] Biological: fludarabine phosphate Interventions: B-Cell Chronic Lymphocytic Leukemia Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label;",
    "textAfterTable": "Participant Flow for 3 periods Period 1: \u00a0 Treatment Period \u00a0 \u00a0 Combination Arm (FluCAM) \u00a0 \u00a0 Fludarabine Alone \u00a0 STARTED \u00a0 \u00a0 168 \u00a0 \u00a0 167 \u00a0 Safety Population \u00a0 \u00a0 164 [1] \u00a0 165 [2] COMPLETED \u00a0 \u00a0 103 [3] \u00a0 107 [4] NOT COMPLETED \u00a0 \u00a0 65 \u00a0 \u00a0 60 \u00a0 Disease progression \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 9 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 8 \u00a0 Unable to comply with protocol \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}